Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thiago Licias de Oliveira | M | - | 3 years | |
| Leslie Miller | F | 43 | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Healy | M | 59 |
Edge Therapeutics, Inc.
 Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 3 years |
| Geoffrey Parker | M | 59 | 3 years | |
| Elder Granger | M | 70 | 3 years | |
| Anders Hove | M | 58 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 1 years |
| Gene C. Mack | M | 50 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 2 years |
| Rosemary Crane | F | 64 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 2 years |
| Liam Ratcliffe | M | 60 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 3 years |
| Andrew Einhorn | M | 64 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 3 years |
| Mark Heinen | M | 54 | 2 years | |
| W. Middlekauff | M | 63 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | - |
| Risa Lavizzo-Mourey | M | 69 | 3 years | |
| Andrew Armanino | M | 59 | 3 years | |
| Richard Traynor | M | 53 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 1 years |
| Renu Vaish | F | - |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | - |
| Su Ying Liu | M | 35 | 2 years | |
| Alyssa Wyant | F | 49 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | - |
| Paul D'Angio | M | 65 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 2 years |
| Noriko Tojo | F | 60 |
Otsuka America, Inc.
 Otsuka America, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America, Inc. operates as a holding company for Otsuka America Pharmaceutical. Its primary objective is to bring products to the U.S. market developed by Otsuka America Pharmaceutical's Japanese parent company, Otsuka Pharmaceutical Co., Ltd. Those products center on treating neurological and cardiovascular diseases. The company was founded in 1989 and is headquartered in San Francisco, CA. | - |
| Daniel Brennan | M | 56 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 2 years |
| Andrew Saik | M | 54 |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | 2 years |
| Harry Sacks | M | - |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | - |
| Atsumasa Makise | M | 66 |
Otsuka America, Inc.
Otsuka America, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America, Inc. operates as a holding company for Otsuka America Pharmaceutical. Its primary objective is to bring products to the U.S. market developed by Otsuka America Pharmaceutical's Japanese parent company, Otsuka Pharmaceutical Co., Ltd. Those products center on treating neurological and cardiovascular diseases. The company was founded in 1989 and is headquartered in San Francisco, CA. | - |
| Masayuki Kobayashi | M | 57 |
Otsuka America, Inc.
Otsuka America, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America, Inc. operates as a holding company for Otsuka America Pharmaceutical. Its primary objective is to bring products to the U.S. market developed by Otsuka America Pharmaceutical's Japanese parent company, Otsuka Pharmaceutical Co., Ltd. Those products center on treating neurological and cardiovascular diseases. The company was founded in 1989 and is headquartered in San Francisco, CA. | - |
| Gregory W. Gin | M | - |
Edge Therapeutics, Inc.
Edge Therapeutics, Inc. BiotechnologyHealth Technology Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. | - |
| Paul Freiman | M | 89 |
Otsuka America, Inc.
Otsuka America, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America, Inc. operates as a holding company for Otsuka America Pharmaceutical. Its primary objective is to bring products to the U.S. market developed by Otsuka America Pharmaceutical's Japanese parent company, Otsuka Pharmaceutical Co., Ltd. Those products center on treating neurological and cardiovascular diseases. The company was founded in 1989 and is headquartered in San Francisco, CA. | - |
| Deepti Sodhi Jaggi | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 28 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Justin Zamirowski
- Personal Network
